Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recurrence × tislelizumab × Clear all

Phase

Phase 2 4 Phase NA 1 Phase 4 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 9 Stomach Neoplasms 6 Neoplasm Metastasis 4 Carcinoma, Non-Small-Cell Lung 4 Carcinoma, Hepatocellular 4 Solid Tumor 3 Neoplasms 3 Breast Neoplasms 3 Triple Negative Breast Neoplasms 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, Extranodal NK-T-Cell 2 Lung Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Carcinoma, Transitional Cell 2 Advanced Solid Tumors 2 Advanced Solid Tumor 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Small Cell Lung Cancer Extensive Stage 1 Sarcoma 1 Recurrence 1 Pancreatic Neoplasms 1 Neuroendocrine Tumors 1 Muscle Invasive Bladder Cancer 1 Melanoma 1

Interventions

Dexamethasone 33 Cyclophosphamide 29 venetoclax 18 fludarabine 18 Lenalidomide 16 Bortezomib 16 Cytarabine 13 pembrolizumab 12 Calcium Dobesilate 12 Carboplatin 11 fludarabine phosphate 10 pomalidomide 9 Rituximab 9 Gemcitabine 9 Nivolumab 8 Azacitidine 7 daratumumab 6 carfilzomib 6 blinatumomab 6 Decitabine 6 Bendamustine Hydrochloride 6 selinexor 5 obinutuzumab 5 ibrutinib 5 Vincristine 5 Temozolomide 5 Methotrexate 5 Etoposide 5 Cisplatin 5 tafasitamab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07502768 2026-03-31

EpiRev-NKT

Fudan University

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡